Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells MXHDfZRwfG:6aXPpeJkh[XO|YYm= Mkj1O|IhcA>? MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0yOiCwTR?= NF\WPVgyQTZ3NESwPC=>
RS4-11 cells M3TYNmZ2dmO2aX;uJIF{e2G7 NGPpSZYzKGh? NX62[G1RUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDSV|QuOTFiY3XscJMh[W[2ZYKgNkBpenNiYomg[Yxm[3S{b3Po[Y1qdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwQVE{KG6P NWLxcWFwOTl4NUS0NFg>
CGTH-W-1 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MofqTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQzNjZ3IN88US=> M2XxV3NCVkeHUh?=
SW982 cell M3uwcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1z5eGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20OU42QCEQvF2= MkjxV2FPT0WU
human EoL-1-cell cell NUT4To1iT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVzJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5yODDuUS=> NEXzclBUSU6JRWK=
MOLM-13 cells M{P1XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXO3NkBp NHrKfHpKdmirYnn0bY9vKG:oIF\MWFMhUVSGIHjleIVzd3q7Z3;1d{BufXSjboSgbY4hcHWvYX6gUW9NVS1zMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUC9NE4xPTVizszN NYjNfYRTOjZyOEGwNlM>
KASUMI-1 cell MnHyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWnVfGwxUW6qaXLpeIlwdiCxZjDoeY1idiCNQWPVUWkuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[wNVYh|ryP M3rENHNCVkeHUh?=
NCI-H1755 cell NYLSVGNvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODZ{N{Og{txO M2HGeXNCVkeHUh?=
human MES-SA cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJG1GWy2VQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFc2PDRizszN NV3jNJdjW0GQR1XS
human HCC1395 cell NX\pUI5CT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnPlTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzM{m1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDR{ODFOwG0> NUTSbGY1W0GQR1XS
human D-336MG cell M3nN[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MofTTY5pcWKrdHnvckBw\iCqdX3hckBFNTN|Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDd3NDFOwG0> MVzTRW5ITVJ?
CHP-212 cell NXfJWlh1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHn5N3lKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6N{ezJO69VQ>? MW\TRW5ITVJ?
human KM12 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2njfWlvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFkzPzVizszN NIfhVZZUSU6JRWK=
A204 cell NXv4ZXROT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoPVTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNFA2OiEQvF2= MkDJV2FPT0WU
CAL-51 cell Mn\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlOxTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExPzB7IN88US=> M3qyN3NCVkeHUh?=
human A431 cell MmKyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoDNTY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVIyPiEQvF2= MYDTRW5ITVJ?
NCI-H650 cell M{POc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2HtcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFzN{C4JO69VQ>? NH60d4NUSU6JRWK=
A427 cell M1vsRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoH0TY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVkyQCEQvF2= M2ny[HNCVkeHUh?=
human 769-P cell M370[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH:2dI5KdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjB6MjFOwG0> MnHOV2FPT0WU
SW1710 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVzJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM{OTZizszN MnX6V2FPT0WU
human H4 cell NIDHOGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zM{m2N{DPxE1? M3\GW3NCVkeHUh?=
HT-1080 cell NILXO2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2QTh{IN88US=> M4PBRXNCVkeHUh?=
human PANC-03-27 cell M{fQd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mk\FTY5pcWKrdHnvckBw\iCqdX3hckBRSU6FLUCzMVI4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNkCyJO69VQ>? MnG1V2FPT0WU
A375 cells NHTYdWlEgXSxdH;4bYNqfHliYYPzZZk> NYjHZ|F7PzJiaB?= Mn7ZWI95cWOrdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;MD6xPEDPxE1? MnvCNVk3PTR2MEi=
human HOP-62 cell M321W2Z2dmO2aX;uJIF{e2G7 M1HhWGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQDB5MzFOwG0> M4i5c3NCVkeHUh?=
human U031 cell MkfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3PufWlvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk3QThizszN NILjdlZUSU6JRWK=
mouse BAF3 cells MYLQdo9tcW[ncnH0bY9vKGG|c3H5 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNidILhcpNnd3KvZXSge4l1cCCcTl[xPVguTkeIUkGgZ49ve3S{dXP0MEBKSzVyPUCuNkDPxE1? MU[yNVk{PjV2Mh?=
human G-402 cell NYnoNIYxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUKzRopYUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB{NUOg{txO MV;TRW5ITVJ?
human G-361 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4DWOGlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxQDV|IN88US=> M3TtRnNCVkeHUh?=
NCI-H810 cell NVnEXnp1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn7ZTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjFyMkeg{txO NXK0UZF3W0GQR1XS
NCI-H2030 cell MmLkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M37TVmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{CwOkDPxE1? MUDTRW5ITVJ?
human HCT-116 cell NGLab5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{CybGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN3Nkig{txO Ml3SV2FPT0WU
human SNU-423 cell NFT4cllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS12MkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PjV5IN88US=> NYjOVHNZW0GQR1XS
human SCC-4 cell M3PabWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUTSWHFvUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN7Nkeg{txO NFvLRXNUSU6JRWK=
human SW48 cell NU\uSndyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2LUUWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlY3QCEQvF2= NX6wTHI6W0GQR1XS
human SF295 cell NHy5NXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXZTY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlczPTdizszN NWTDcXFTW0GQR1XS
MDA-MB-231 cell M1HtT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml3JTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{OEGwNUDPxE1? MVXTRW5ITVJ?
A172 cell MnfaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVTJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK5NVUh|ryP NVfSNIk3W0GQR1XS
human BCPAP cell M2f6NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPzR|JKdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTh5OTFOwG0> M1T2T3NCVkeHUh?=
human COLO-792 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3nSbGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ7OUeyJO69VQ>? MV\TRW5ITVJ?
human DU-145 cell MkHmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|E5QDlizszN MVXTRW5ITVJ?
NCI-H2122 cell NEDTbpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{OEWg{txO M12zVHNCVkeHUh?=
human SK-UT-1 cell MoL1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M125XGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ7NUKg{txO NEfyT21USU6JRWK=
LXF-289 cell Mn;6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTZ3IN88US=> NX\xPXE6W0GQR1XS
human NCI-H1792 cell M2PRdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzNyOU[g{txO NWPw[ndYW0GQR1XS
MCF7 cell NHXWephIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzNlc1KM7:TR?= MXHTRW5ITVJ?
HCT-15 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWXzfo1TUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|NEOyJO69VQ>? Mmj6V2FPT0WU
human NCI-H358 cell NIqzUlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> M3P0T3NCVkeHUh?=
human HLE cell MnfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLiOZZKUW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PzV{IN88US=> NELlOHFUSU6JRWK=
human SW1088 cell MkfhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2nMbGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ozd7NzFOwG0> NH;NdIRUSU6JRWK=
human K5 cell NEixRZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|NkG0PUDPxE1? M4PjeHNCVkeHUh?=
human SR cell MnvNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vwUGlvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2OVcyKM7:TR?= M{C4RXNCVkeHUh?=
human Calu-3 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnPYTY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3QDJ3IN88US=> MYHTRW5ITVJ?
human SK-MEL-30 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXr4WYsyUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO5PVE{KM7:TR?= NGr1e4tUSU6JRWK=
human SW780 cell MnnQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HQd2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyOTR{IN88US=> MYTTRW5ITVJ?
NCI-H1563 cell NIi3T5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{LEZmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MUS4OEDPxE1? MVjTRW5ITVJ?
human MKN45 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIr1SoZKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTl|MTFOwG0> M2fFPHNCVkeHUh?=
MDA-MB-157 cell M1fENmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2fDUmlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKwNVUh|ryP NFvsSGZUSU6JRWK=
human NCI-H522 cell NUDjWo5qT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NECxfndKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO NFPDPHBUSU6JRWK=
human A2780 cell NV;vSHNYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3f1PWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4PTB|IN88US=> NUP4c|JHW0GQR1XS
human A498 cell M2f0WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHnvOYhKdmirYnn0bY9vKG:oIHj1cYFvKEF2OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4Pjl|IN88US=> MlHEV2FPT0WU
human BxPC-3 cell Mn;4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXPCR4VLUW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7M{[2JO69VQ>? MYrTRW5ITVJ?
human A2058 cell NVvISYNuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXLJcohq[mm2aX;uJI9nKGi3bXHuJGEzODV6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61Nlg1PCEQvF2= MUjTRW5ITVJ?
human PC-14 cell NXfHdYs{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61N|g2PSEQvF2= MoDlV2FPT0WU
human KG-1 cell NXfkUYhrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW1OFE6KM7:TR?= Ml;DV2FPT0WU
human A375 cell NGDUc|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MljDTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61OlExOyEQvF2= NHjSeGhUSU6JRWK=
human SW1783 cell NETxVHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2WxemlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzN5IN88US=> NULGXHpXW0GQR1XS
human MKN1 cell M{f2W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;zOodKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg5PDF{IN88US=> M2TxSHNCVkeHUh?=
NCI-H1650 cell MnXmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7xcphKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEi5NVbkiIEQvF2= NFTNWXBUSU6JRWK=
human HT-1376 cell MkXCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33ifmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUO3OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTJ7MUig{txO NHS1bpFUSU6JRWK=
SW872 cell NXzpbnlyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGDFXVRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PDR3OTFOwG0> NWn2cI93W0GQR1XS
human RT-112 cell MlmzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFzjepVKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTd2OEOg{txO MUHTRW5ITVJ?
human HT-29 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojkTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVc6QTZizszN NInBVXhUSU6JRWK=
human U-266 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1\sTmlvcGmkaYTpc44hd2ZiaIXtZY4hXS1{Nk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5OzB{IN88US=> MkHXV2FPT0WU
human HEL cell NF;rOGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnLMTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4OVE4KM7:TR?= NVixdotMW0GQR1XS
human KU812 cell NEC3XHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUjhVYpPUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTFzNkSg{txO M3fobHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID